top of page

Imugene Pushes Biotech Trend

Investor favourite Imugene has rose almost 10% today after the company announced an integral clinical trial update for their shareholders.

The company provided an update on its clinical trial of its oncolytic virotherapy candidate, Checkvacc. The treatment aims to activate the immune system of cancer patients to treat and eradicate tumours.

Imugene advised that City of Hope has dosed the first patient from the third group of participants in the Checkvacc phase 1 clinical trial. City of Hope is one of the largest cancer research and treatment organisations in the United States.

The Checkvacc study is recruiting patients who suffer from triple negative breast cancer (TNBC). The primary goal of the study is to determine safety limits and decide on the optimal dosage of Checkvacc against metastatic TNBC.

Imugene noted that the current trial design involves a dose escalation. Thereafter, an expanded group of 12 patients will receive the final dose.

Managing director and CEO Leslie Chong said:

“We are pleased with the continued progress being made in this trial as we dose the first patient in cohort 3.

From cohorts 1 & 2 we’ve continued to see early positive results in oncolytic virus infection and replication in the TNBC tumours and importantly there remains no observed toxicity. Checkvacc has the potential to improve clinical response and survival in this indication where there are currently no meaningful treatments, and we are eager to deliver on that.”

bottom of page